Related references
Note: Only part of the references are listed.Randomized Phase II Trial of the Cyclin-Dependent Kinase Inhibitor Dinaciclib (MK-7965) Versus Capecitabine in Patients With Advanced Breast Cancer
Monica M. Mita et al.
CLINICAL BREAST CANCER (2014)
Dinaciclib (SCH727965) Inhibits the Unfolded Protein Response through a CDK1-and 5-Dependent Mechanism
Tri K. Nguyen et al.
MOLECULAR CANCER THERAPEUTICS (2014)
Randomized phase 2 study of the cyclin-dependent kinase inhibitor dinaciclib (MK-7965) versus erlotinib in patients with non-small cell lung cancer
Joe J. Stephenson et al.
LUNG CANCER (2014)
Cyclin-Dependent Kinase Inhibitor Dinaciclib Interacts with the Acetyl-Lysine Recognition Site of Bromodomains
Mathew P. Martin et al.
ACS CHEMICAL BIOLOGY (2013)
Clinical and laboratory studies of the novel cyclin-dependent kinase inhibitor dinaciclib (SCH 727965) in acute leukemias
Ivana Gojo et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2013)
Targeting cyclin-dependent kinases in anti-neoplastic therapy
Celine Bruyere et al.
CURRENT OPINION IN CELL BIOLOGY (2013)
ATP-noncompetitive CDK inhibitors for cancer therapy: an overview
Agnese Anna Abate et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2013)
A first-in-human, phase 1, dose-escalation study of dinaciclib, a novel cyclin-dependent kinase inhibitor, administered weekly in subjects with advanced malignancies
John J. Nemunaitis et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2013)
The Anti-Melanoma Activity of Dinaciclib, a Cyclin-Dependent Kinase Inhibitor, Is Dependent on p53 Signaling
Brijal M. Desai et al.
PLOS ONE (2013)
Flavopiridol Synergizes with Sorafenib to Induce Cytotoxicity and Potentiate Antitumorigenic Activity in EGFR/HER-2 and Mutant RAS/RAF Breast Cancer Model Systems
Teddy S. Nagaria et al.
NEOPLASIA (2013)
Therapeutic response to CDK4/6 inhibition in breast cancer defined by ex vivo analyses of human tumors
Jeffry L. Dean et al.
CELL CYCLE (2012)
Phase I, Dose-Escalation Trial of the Oral Cyclin-Dependent Kinase 4/6 Inhibitor PD 0332991, Administered Using a 21-Day Schedule in Patients with Advanced Cancer
Keith T. Flaherty et al.
CLINICAL CANCER RESEARCH (2012)
MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition
Dai Horiuchi et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2012)
The novel cyclin-dependent kinase inhibitor dinaciclib (SCH727965) promotes apoptosis and abrogates microenvironmental cytokine protection in chronic lymphocytic leukemia cells
A. J. Johnson et al.
LEUKEMIA (2012)
Initial testing (stage 1) of the cyclin dependent kinase inhibitor SCH 727965 (dinaciclib) by the pediatric preclinical testing program
Richard Gorlick et al.
PEDIATRIC BLOOD & CANCER (2012)
Anti-angiogenic effects of purine inhibitors of cyclin dependent kinases
Johanna Liebl et al.
ANGIOGENESIS (2011)
Molecular and cellular effects of multi-targeted cyclin-dependent kinase inhibition in myeloma: biological and clinical implications
Douglas W. McMillin et al.
BRITISH JOURNAL OF HAEMATOLOGY (2011)
Cyclin-dependent kinase inhibitor Dinaciclib (SCH727965) inhibits pancreatic cancer growth and progression in murine xenograft models
Georg Feldmann et al.
CANCER BIOLOGY & THERAPY (2011)
Expression analysis and molecular targeting of cyclin-dependent kinases in advanced melanoma Functional analysis and molecular targeting of cyclin-dependent kinase family members in advanced melanoma
Christopher Abdullah et al.
CELL CYCLE (2011)
Promotion of Apoptosis in Cancer Cells by Selective Purine-Derived Pharmacological CDK Inhibitors: One Outcome, Many Mechanisms
Jozefa Wasierska-Gadek et al.
CURRENT PHARMACEUTICAL DESIGN (2011)
The CDK inhibitors in cancer research and therapy
Jonas Cicenas et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2011)
The Cyclin-Dependent Kinase Inhibitor SCH 727965 (Dinacliclib) Induces the Apoptosis of Osteosarcoma Cells
Wei Fu et al.
MOLECULAR CANCER THERAPEUTICS (2011)
Roscovitine confers tumor suppressive effect on therapy-resistant breast tumor cells
Binoj C. Nair et al.
BREAST CANCER RESEARCH (2011)
A Phase I Study of Flavopiridol in Combination With Gemcitabine and Irinotecan in Patients With Metastatic Cancer
Houman M. Fekrazad et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2010)
Safety, tolerability, pharmacokinetics and pharmacodynamics of the oral cyclin-dependent kinase inhibitor AZD5438 when administered at intermittent and continuous dosing schedules in patients with advanced solid tumours
D. S. Boss et al.
ANNALS OF ONCOLOGY (2010)
Inhibition of MCL-1 in breast cancer cells promotes cell death in vitro and in vivo
Clint Mitchell et al.
CANCER BIOLOGY & THERAPY (2010)
A phase I clinical trial of FOLFIRI in combination with the pan-cyclin-dependent kinase (CDK) inhibitor flavopiridol
Mark A. Dickson et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2010)
Cyclin-dependent kinases (cdks) and the DNA damage response: rationale for cdk inhibitor-chemotherapy combinations as an anticancer strategy for solid tumors
Neil Johnson et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2010)
Dinaciclib (SCH 727965), a Novel and Potent Cyclin-Dependent Kinase Inhibitor
David Parry et al.
MOLECULAR CANCER THERAPEUTICS (2010)
Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia
Mitch A. Phelps et al.
BLOOD (2009)
Phase I Study of Flavopiridol with Oxaliplatin and Fluorouracil/Leucovorin in Advanced Solid Tumors
Dana Rathkopf et al.
CLINICAL CANCER RESEARCH (2009)
Apoptosis of metastatic prostate cancer cells by a combination of cyclin-dependent kinase and AKT inhibitors
Subhra Mohapatra et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2009)
Phase II Study of Flavopiridol in Relapsed Chronic Lymphocytic Leukemia Demonstrating High Response Rates in Genetically High-Risk Disease
Thomas S. Lin et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Cell cycle control of pituitary development and disease
Victor Quereda et al.
JOURNAL OF MOLECULAR ENDOCRINOLOGY (2009)
Cell cycle, CDKs and cancer: a changing paradigm
Marcos Malumbres et al.
NATURE REVIEWS CANCER (2009)
An unusual member of the Cdk family: Cdk5
Fatema A. Dhariwala et al.
CELLULAR AND MOLECULAR NEUROBIOLOGY (2008)
Phase I dose-finding study of weekly docetaxel followed by flavopiridol for patients with advanced solid tumors
M. N. Fornier et al.
CLINICAL CANCER RESEARCH (2007)
Cell cycle kinases in cancer
Marcos Malumbres et al.
CURRENT OPINION IN GENETICS & DEVELOPMENT (2007)
A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days
C. Benson et al.
BRITISH JOURNAL OF CANCER (2007)
Cyclin-dependent kinase pathways as targets for cancer treatment
GI Shapiro
JOURNAL OF CLINICAL ONCOLOGY (2006)
Cyclin-dependent kinase inhibitor Roscovitine induces apoptosis in chronic lymphocytic leukemia cells
IN Hahntow et al.
LEUKEMIA (2004)
Phase I clinical and pharmacokinetic study of flavopiridol administered as a daily 1-hour infusion in patients with advanced neoplasms
AR Tan et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Review of flavopiridol, a cyclin-dependent kinase inhibitor, as breast cancer therapy
AR Tan et al.
SEMINARS IN ONCOLOGY (2002)
Regulation of RNA polymerase II activity by CTD phosphorylation and cell cycle control
T Oelgeschläger
JOURNAL OF CELLULAR PHYSIOLOGY (2002)
Structure-based design of cyclin-dependent kinase inhibitors
TG Davies et al.
PHARMACOLOGY & THERAPEUTICS (2002)
Share Paper
